104 related articles for article (PubMed ID: 11989255)
1. [Chemotherapy of hematological malignancies based on EBM].
Ueda R
Nihon Naika Gakkai Zasshi; 2002 Mar; 91 Suppl():147-53. PubMed ID: 11989255
[No Abstract] [Full Text] [Related]
2. [Chemotherapy based on EBM in the field of hematological malignancies].
Ogura M; Takeuchi H; Ueda R
Gan To Kagaku Ryoho; 2000 Jan; 27(1):14-29. PubMed ID: 10660730
[TBL] [Abstract][Full Text] [Related]
3. Second biannual report of the Cochrane Haematological Malignancies Group.
Kober T; Bohlius J; Trelle S; Engert A
J Natl Cancer Inst; 2005 Apr; 97(7):E1. PubMed ID: 15812063
[No Abstract] [Full Text] [Related]
4. Sixth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin lymphoma.
Weingart O; Rehan FA; Schulz H; Naumann F; Knauel I; Bohlius CB; Engert A
J Natl Cancer Inst; 2007 Sep; 99(17):E1. PubMed ID: 17728205
[No Abstract] [Full Text] [Related]
5. Third biannual report of the Cochrane Haematological Malignancies Group.
Kober T; Skoetz N; Trelle S; Bohlius J; Engert A;
J Natl Cancer Inst; 2005 Aug; 97(16):E2. PubMed ID: 16106014
[No Abstract] [Full Text] [Related]
6. [Effective clinical use of cyclophosphamide in hematological malignancies].
Miyazaki H; Hirano M
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1891-5. PubMed ID: 8978792
[TBL] [Abstract][Full Text] [Related]
7. Fourth biannual report of the Cochrane Haematological Malignancies Group.
Kober T; Hülsewede H; Bohlius J; Engert A
J Natl Cancer Inst; 2006 Apr; 98(8):E1. PubMed ID: 16622111
[No Abstract] [Full Text] [Related]
8. Possible role of toll-like receptor 9 polymorphism in chemotherapy-related invasive mold infections in children with hematological malignancies.
Lanciotti M; Pigullo S; Lanza T; Dufour C; Caviglia I; Castagnola E
Pediatr Blood Cancer; 2008 Apr; 50(4):944. PubMed ID: 17894360
[No Abstract] [Full Text] [Related]
9. Procarbazine in haematology: an old drug with a new life?
Massoud M; Armand JP; Ribrag V
Eur J Cancer; 2004 Sep; 40(13):1924-7. PubMed ID: 15315798
[TBL] [Abstract][Full Text] [Related]
10. [Gastric cancer].
Kinoshita T; Konishi M; Nakagohri T; Takahashi S; Gotouda N
Gan To Kagaku Ryoho; 2006 Mar; 33(3):313-7. PubMed ID: 16531710
[TBL] [Abstract][Full Text] [Related]
11. [Standard chemotherapy for gastric cancer].
Sasaki T; Kobayashi T; Okamoto R; Omuro Y
Nihon Rinsho; 2001 Apr; 59 Suppl 4():350-7. PubMed ID: 11424405
[No Abstract] [Full Text] [Related]
12. [Potential for reduced intensity conditioning regimens for paediatric malignancies].
Paillard C; Bay JO; Dalle JH; Michel G; Bordigoni P; Kanold J
Arch Pediatr; 2007 Feb; 14(2):200-1. PubMed ID: 17184980
[No Abstract] [Full Text] [Related]
13. Chemotherapy in non-small cell lung cancer: an update of an individual patient data-based meta-analysis.
Burdett S; Stewart L; Pignon JP
J Thorac Cardiovasc Surg; 2005 May; 129(5):1205; author reply 1205-6. PubMed ID: 15867822
[No Abstract] [Full Text] [Related]
14. [Trends in development of molecular targeted therapy for hematological neoplasms].
Nagai T
Rinsho Ketsueki; 2012 Oct; 53(10):1768-75. PubMed ID: 23037750
[No Abstract] [Full Text] [Related]
15. [Standard chemotherapy for gastrointestinal malignancies based on evidence].
Sasaki T; Maeda Y; Kobayashi T; Okamoto R; Omuro Y; Takada N
Gan To Kagaku Ryoho; 2000 Feb; 27(2):166-76. PubMed ID: 10700886
[TBL] [Abstract][Full Text] [Related]
16. [Combined modality treatment of chemotherapy and radiotherapy for unresectable non-small cell lung cancer].
Kubota K
Gan To Kagaku Ryoho; 1997 Oct; 24 Suppl 3():384-9. PubMed ID: 9369912
[TBL] [Abstract][Full Text] [Related]
17. The need for adverse effects reporting standards in oncology clinical trials.
Trotti A; Bentzen SM
J Clin Oncol; 2004 Jan; 22(1):19-22. PubMed ID: 14657230
[No Abstract] [Full Text] [Related]
18. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
Ballester OF; Agaliotis DP; Hiemenz JW; Janssen WE; Fields KK; Zorksy PE; Goldstein SC; Perkins JB; Elfenbein GJ
Bone Marrow Transplant; 1996 Jul; 18(1):9-14. PubMed ID: 8831989
[TBL] [Abstract][Full Text] [Related]
19. Serum selenium deficiency in patients with hematological malignancies: is a supplementation study mandatory?
Muecke R; Micke O; Schomburg L; Buentzel J; Adamietz IA; Huebner J;
Acta Haematol; 2014; 132(2):256-8. PubMed ID: 24903215
[No Abstract] [Full Text] [Related]
20. Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma.
Sonpavde G; Rosenberg JE; Hahn NM; Galsky MD; Bangs R; Sternberg CN; Vogelzang NJ
J Clin Oncol; 2010 May; 28(13):e205-7; author reply e208. PubMed ID: 20159797
[No Abstract] [Full Text] [Related]
[Next] [New Search]
